SCHEMBL710297

SCHEMBL710297

COC[C@H](C)Oc1cc(OCc2ccccc2F)cc(-c2nc3cc(-c4cccnc4)cnc3[nH]2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.38
CYP11B1 P15538 1/20 0.36
MAPT P10636 3/20 0.36
KDM4E B2RXH2 2/20 0.36
NPC1 O15118 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
STAT1 P42224 1/20 0.36
RAB9A P51151 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
GCK P35557 4/20 0.36
CDK1 P06493 1/20 0.36
RET P07949 1/20 0.36
KDR P35968 1/20 0.36
KIT P10721 3/20 0.35
CYP1A1 P04798 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP1B1 Q16678 1/20 0.34
MAPK1 P28482 2/20 0.33
NPSR1 Q6W5P4 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL710298 1.00 EGFR (0.38) EGFRCYP11B1MAPTKDM4ENPC1
SCHEMBL709551 0.89 GCK (0.38) EGFRMAPTKDM4ENPC1RAB9A
SCHEMBL2085435 0.89 GCK (0.38) EGFRMAPTKDM4ENPC1RAB9A
SCHEMBL709552 0.89 GCK (0.38) EGFRMAPTKDM4ENPC1RAB9A
SCHEMBL711480 0.86 GCK (0.38) EGFRMAPTKDM4ENPC1HPGD
SCHEMBL708887 0.86 GCK (0.38) EGFRMAPTKDM4ENPC1RAB9A
SCHEMBL712325 0.86 GCK (0.38) EGFRMAPTKDM4ENPC1HPGD
SCHEMBL708888 0.86 GCK (0.38) EGFRMAPTKDM4ENPC1RAB9A
SCHEMBL711479 0.86 GCK (0.38) EGFRMAPTKDM4ENPC1HPGD
SCHEMBL713365 0.84 GCK (0.38) MAPTKDM4ENPC1RAB9AGCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1940837-B1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL (JP) 2012-11-07 EP disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK EGFR 4391/4885CYP11B1 1421/4885MAPT 3003/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.